The pro-survival protein Bcl-2, whose expression is frequently upregulated in CLL as a result of deletion of mir15-a/mir16-1, located at 13q14 and known to target BCL-2 mRNA (43), had long been viewed as a promising target for CLL therapy. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.